Comparing somatostatin analogue therapy versus observation after PRRT for neuroendocrine tumors
Part of Cancer clinical trials.
This trial tests whether taking a somatostatin analogue (a drug that slows tumor growth) after PRRT (a type of radiation therapy targeted at tumor cells) is better than just watching and waiting. It is for people with advanced neuroendocrine tumors that are not causing hormone-related symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a neuroendocrine tumor (a type of cancer that grows slowly) that has spread and cannot be removed with surgery.
- Your tumor is well or moderately differentiated (a measure of how abnormal the cells look under a microscope).
- You are scheduled to receive or have already received up to 3 doses of PRRT (a targeted radiation treatment).
- You are at least 18 years old.
- You are generally able to care for yourself (ECOG performance status 0-2 or Karnofsky score at least 60%).
- If you have had brain metastases (tumors that spread to the brain), they must have been treated and stable for at least 4 weeks, and you must be off steroids for at least 1 month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
This Phase 2 study compares a more personalized (precision) radiation dose plan to the standard dose plan using Lu-177-DOTATOC for people with neuroendocrine neoplasms (NEN) that have worsened or caused major symptoms despite usual treatments. The goal is to see if better planning can improve treatment delivery while staying safe.
This trial studies whether it’s helpful to keep taking somatostatin “analog” injections even after your neuroendocrine tumor has started growing despite the usual dose. It also looks at how the next treatment choice (targeted pills or PRRT) fits in for people with non-functional, well-differentiated GEP NET.
This trial tests whether it's safe to stop somatostatin analogues (SSAs) after PRRT (a type of radiation therapy for neuroendocrine tumors). It is for people with midgut, hindgut, or pancreatic NETs that have not responded to SSAs and now need PRRT.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Hear when a new Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.